{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/04/18/3276558/0/fr/Communiqu%C3%A9-de-presse-ESCMID-Le-Nuvaxovid-vaccin-contre-la-COVID-19-de-Sanofi-a-montr%C3%A9-une-meilleure-tol%C3%A9rance-que-le-mNEXSPIKE-dans-une-%C3%A9tude-comparative-directe.html", "message": "News view counter 670572 successfully enlarged"}